Omzo vs MedVi: Clinician-Guided Care or Promo-Priced Simplicity
Looking for a telehealth GLP-1 option? In short: Omzo emphasizes clinician-guided, personalized plans with compounded semaglutide and a tirzepatide option, starting at $179, while MedVi emphasizes a simple online process and a $179 promotional first month for compounded semaglutide but has higher ongoing rates. Early verdict: choose Omzo for clinician-guided plans and multiple medication options, or choose MedVi for the lowest promotional entry price and a no clinic visit workflow.
Explore Omzo clinician-guided plans
Omzo vs MedVi: three key differences at a glance
This comparison focuses on three clear differences supported by the sources: medication options, pricing and promotional structure, and care model and support. Where the source does not supply information we do not invent it.
1) Medication options and regulatory notes
Omzo connects users to licensed U.S. providers who may prescribe either compounded semaglutide or write prescriptions for branded medications. Omzo explicitly states its Compounded Medication Program provides access to compounded drugs that are not FDA approved and that branded prescriptions must be filled at a pharmacy by the patient. MedVi offers clinically dosed compounded semaglutide only and notes its compounds are produced in FDA regulated facilities but are not FDA approved. Both providers state compounded medications are not FDA approved and users should consult providers about risks and benefits.
Start MedVi online intake and see price details
2) Pricing structure and promotions
Both providers show a $179 figure but the context differs. Omzo lists semaglutide starting at $179 and tirzepatide starting at $279 as platform pricing points. MedVi advertises a winter promotional first month of $179 including fast, free shipping, and its sources note the ongoing standalone month rises to $299 with a three month plan at $649 available. The MedVi FAQ explicitly warns the ongoing price is substantially higher than the first-month promo.
3) Care model, clinician review, and support
Omzo emphasizes clinician-guided plans reviewed by licensed U.S. providers and notes clinical services are provided by third party networks of U.S. licensed clinicians who determine eligibility and make final prescribing decisions. MedVi emphasizes a simple online process with no clinic visits, a licensed clinician review after checkout, and 24/7 support from certified medical professionals. MedVi also notes clinicians retain prescription discretion and that the program includes physician review and a personalized plan for the first-month price.
Side-by-side comparison table
| Criteria | Omzo | MedVi |
|---|---|---|
| Starting price | Semaglutide starting at $179; tirzepatide starting at $279 | Promotional first month $179; ongoing month $299; three-month plan $649 |
| Medication types | Compounded semaglutide and tirzepatide; providers may prescribe branded meds | Clinically dosed compounded semaglutide only |
| Compounded regulatory note | Compounded medications are not FDA approved | Compounded medications are not FDA approved |
| Care model | Clinician-guided plans reviewed by licensed U.S. providers | Simple online intake, no clinic visits, clinician review and 24/7 support |
| Shipping and logistics | Fast, discreet delivery; medication costs included in fees paid to Omzo | Fast, free shipping on promotional month; medication included in program cost |
| Notable limits | Compounded drugs are not FDA approved; eligibility, pricing and state availability may change | First-month price is promotional and ongoing price increases; semaglutide only |
What the providers say about outcomes and guarantees
Omzo notes user results reflect internal statistics from paid orders and that results may vary. Omzo states no guarantees and that individual results are influenced by many factors. MedVi cites self-reported patient data and notes results vary based on adherence and clinician recommendations; MedVi does not publish an outcome guarantee and warns results are not typical.
See Omzo medication options and policies
How to choose: Prospective user scenarios
Compare the two providers on the priorities below and match to your needs.
- Want multiple medication paths including tirzepatide or a branded prescription option? Omzo provides tirzepatide listing and allows providers to write prescriptions for branded medications to be filled by the patient.
- Want the lowest first-step cost and a fully online intake with no clinic visits? MedVi lists a $179 promotional first month with fast, free shipping and a no clinic visit workflow.
- Care and ongoing support matters? Omzo emphasizes clinician-guided plans reviewed by licensed U.S. providers; MedVi highlights 24/7 certified medical support after its online intake.
Compare MedVi program details and support
Conclusion: Omzo vs MedVi
In this comparison Omzo is stronger on clinician-guided plans and a broader set of medication options, including tirzepatide and the possibility of branded prescriptions, with semaglutide starting at $179. MedVi is positioned around a low promotional first month at $179, a simple online process with no clinic visits, and 24/7 support, but its sources warn ongoing costs are higher after the promo. Both use compounded semaglutide options that are not FDA approved and both require clinician review before prescribing.
Choose Omzo if…
You want clinician-guided plans reviewed by licensed U.S. providers, access to compounded semaglutide and tirzepatide options, or a provider who may prescribe branded medications that you fill separately. Verify state availability, pricing, and eligibility before enrollment.
Choose MedVi if…
You prioritize the lowest promotional entry price and a simple online intake with no clinic visits, plus 24/7 certified medical support, and you accept that the ongoing price may be higher and that only compounded semaglutide is offered.